A new cancer research facility will be built at the University of NSW.

Bradley Smith, executive director of the Federation of Australian Scientific and Technological Societies (FASTS), has kindly provided us with a breakdown of the individual projects receiving money through NCRIS.

Cell therapy company Living Cell Technologies (ASX:LCT) has raised more than AUD$3 million through a placement of ordinary shares to US shareholders and an Australian investor.

Sunshine Heart (ASX:SHC) has raised AUD$3.3 million through a private placement to fund the development of its C-Pulse heart assist device.

Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI), has received an initial order for its surgical simulation products worth almost $460,000 from a hospital in Hong Kong.

Melbourne oncology drug developer Cytopia (ASX:CYT) has been offered a AUD$3 million federal government Commercial Ready grant to expand clinical development of its lead anti-cancer drug CYT997.

Brisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has raised a total of AUD$10.3 million through a non-renounceable 1:4 entitlements offer.

Sydney-based SSH Medical (ASX:SSH) has started accepting applications for subscriptions to raise approximately $4.3 million to provide working capital for material science company Bio-Layer, which SSH is acquiring.

Unlisted Adelaide-based firm TGR Biosciences has attracted up to AUD$3 million funding from venture capital firm Nanyang Ventures to further clinical development of its treatment for oral mucositis, a debilitating side-effect of cancer treatments.

Biotech companies which have failed to raise enough capital to see them through to the next funding cycle might expire as a funding drought sets in, and blame "shocking" market conditions for forcing them to abandon or change their plans.

Sirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.